View Author
scopus: 7102929253

Wit, R. de

(Ronald de Wit)

Supervisor (promotor) of 3 dissertations


patient cancer treatment chemotherapy survival study docetaxel prostate response trial prostate cancer disease group oncol tumor testicular metastatic month ebm iii baseline factor analysis oncology therapy progression level prognostic model mitoxantrone result ebm iib table phase tumour department metastase testicular cancer prednisone stage cisplatin urology signi marker european regimen research number toxicity cycle fatigue wit r stomach radiation decline tax 327 study outcome score randomized testi bleomycin radiotherapy nomogram retroperitoneal university psa response ebm ib association seminoma surgery hospital resection carcinoma combination center psadt value etoposide serum ficant relapse




10 Most Recent Publications

Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study (Article)
Niraula, S. Pond, G.R. Wit, R. de Eisenberger, M. Tannock, I.F. Joshua, A.M.
2013-02-01
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 (Article)
Santis, M. de Bellmunt, J. Collette, S. Lorent, J. Wit, R. de Sylvester, R. Mead, G.M. Kerst, J.M. Leahy, M. Maroto, P. Gil, T. Marreaud, S. Daugaard, G. Skoneczna, I.
2012-01-10
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer (Article)
Scher, H.I. Jia, X. Meluch, A.A. Nordquist, L.T. Venner, P.M. Heidenreich, A. Chu, L.F. Heller, G. Chi, K.N. Wit, R. de Berry, W.R. Albers, P. Henick, B. Waterhouse, D. Ruether, D.J. Rosen, P.J.
2011-06-01
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974) (Article)
Daugaard, G. Skoneczna, I. Schmoll, H.J. Aass, N. Wit, R. de de Santis, M. Dumez, H. Marreaud, S. Collette, L.A.J. Lluch, J.R.G. Bokemeyer, C.
2011-05-05
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy (Article)
Sonpavde, G. Pond, G.R. Berry, W.R. Wit, R. de Eisenberger, M.A. Tannock, I.F. Armstrong, A.J.
2011-04-06
Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy (Article)
Vos, F.Y.F.L. de Wit, R. de
2010-11-01
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy (Article)
Sonpavde, G. Pond, G.R. Berry, W.R. Wit, R. de Armstrong, A.J. Eisenberger, M.A. Tannock, I.F.
2010-09-30
Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel (Article)
Strijbos, M.H. Gratama, J-W. Schmitz, P.I.M. Rao, C. Onstenk, W. Doyle, G.V. Miller, M.C. Wit, R. de Terstappen, L.W.M.M. Sleijfer, S.
2010-07-01
Urogenitale Oncologie: inspirerende decennia, uitdagende toekomst (Inaugural Lecture)
Wit, R. de
2010-02-26
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival (Article)
Armstrong, A.J. Tannock, I.F. Wit, R. de George, D.J. Eisenberger, M. Halabi, S.
2010-02-01
  • rss icon RSS Publication Feed
  • foaf icon FOAF Profile